CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02132624 |
Recruitment Status :
Completed
First Posted : May 7, 2014
Last Update Posted : October 30, 2017
|
Sponsor:
Uppsala University
Collaborators:
Uppsala University Hospital
Karolinska University Hospital
AFA Insurance
Swedish Cancer Society
Information provided by (Responsible Party):
Uppsala University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | May 31, 2017 |
Actual Study Completion Date : | May 31, 2017 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):